JP MORGAN 2015: Bristol-Myers oncology head boasts PD-1 promise, partners
This article was originally published in Scrip
"The strategy of being able to use immune-oncology to improve outcomes is being realized," Bristol-Myers Squibb head of oncology development Michael Giordano told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.